Neurotensin (NTS) is a 13-amino acid neuropeptide that acts as a neurotransmitter and neuromodulator primarily through two G protein-coupled receptors: NTSR1 (high affinity) and NTSR2 (lower affinity). Neurotensin receptor modulation has emerged as a potential therapeutic strategy for neurodegenerative diseases due to the peptide's broad effects on dopaminergic signaling, neuroinflammation, excitotoxicity, and cellular survival pathways. [1][2]
NTSR1 agonists have demonstrated neuroprotective effects in preclinical models of Parkinson's disease, while NTSR2 modulators show promise for modulating neuroinflammatory responses. The neurotensin system intersects with multiple disease-relevant pathways including dopamine D2 receptor heteroreceptor complexes, MAPK signaling, and calcium homeostasis. [3]
Neurotensin is synthesized as a pre-pro-neurotensin precursor and processed into the mature 13-amino acid active peptide. It is widely distributed in the central nervous system with highest concentrations in the hypothalamus, substantia nigra, ventral tegmental area, and striatum. As a neuromodulator, neurotensin modulates the activity of dopaminergic, GABAergic, and glutamatergic neurons. [4]
NTSR1 (High Affinity):
NTSR2 (Lower Affinity):
NTSR1 agonists represent the primary therapeutic approach for dopaminergic protection in Parkinson's disease. Activation of NTSR1 on dopaminergic neurons promotes survival and modulates striatal dopamine release. [2:1]
Key compounds:
| Compound | Target | Status | Evidence |
|---|---|---|---|
| PD149163 | NTSR1 agonist | Preclinical | Improved motor function in MPTP models |
| ABS-101 | NTSR1 agonist | Preclinical | Neuroprotective in 6-OHDA models |
| Neurotensin(8-13) analogs | Dual NTS1/NTS2 | Preclinical | Enhanced stability, dual receptor activity [3:1] |
Dual-acting ligands may provide broader therapeutic coverage by simultaneously targeting dopaminergic neurons (via NTSR1) and modulating neuroinflammation (via NTSR2). [3:2]
NTSR2-selective compounds target the more widespread receptor to modulate neuroinflammatory responses, potentially benefiting multiple neurodegenerative conditions including Alzheimer's disease and ALS.
NTSR1 activation in the substantia nigra and ventral tegmental area promotes dopaminergic neuron survival through:
NTSR2 activation on microglia and astrocytes modulates inflammatory responses:
Neurotensin receptor activation provides protection against excitotoxic injury through:
Neurotensin receptor modulators show particular promise for Parkinson's disease due to:
Preclinical evidence supports NTSR1 agonism for protecting dopaminergic neurons in animal models of PD. The interaction between neurotensin and dopamine D2 receptors creates opportunities for combination therapies with existing dopaminergic medications. [2:2]
Evidence for neurotensin system alterations in Alzheimer's disease includes:
NTSR1 activation may influence cognitive function through modulation of hippocampal and cortical circuits involved in learning and memory. [@alo2021]
The role of neurotensin in ALS is less well-characterized but may involve:
Current status: Preclinical development
No NTSR1 or NTSR2 modulators have entered clinical trials for neurodegenerative diseases as of 2026. The field remains at the research stage with several academic groups and biotech companies actively investigating neurotensin receptor modulators.
Peptide stability: Neurotensin and its analogs are susceptible to rapid degradation by proteases. Engineering stable analogs is critical for therapeutic development. [3:4]
Blood-brain barrier penetration: As a neuropeptide, neurotensin analogs face challenges crossing the BBB. Strategies include:
Receptor selectivity: Balancing NTSR1 and NTSR2 activity for optimal therapeutic effects requires careful compound design.
Dosing and timing: Determining optimal intervention windows relative to disease stage.
Borroto-Escuela DO, et al. Diversity and bias through dopamine D2R heteroreceptor complexes. Role in Parkinson's disease and schizophrenia. Current Opinion in Pharmacology. 2017. ↩︎ ↩︎
Ferraro L, et al. Neurotensin and Parkinson's disease: a focus on striatal neurotransmission. Journal of Neural Transmission. 2016. ↩︎ ↩︎ ↩︎
Kuhl T, et al. Neurotensin(8-13) analogs as dual NTS1 and NTS2 receptor ligands with enhanced enzyme stability. European Journal of Medicinal Chemistry. 2023. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Tyler-McMahon BM, et al. Neurotensin: role in psychiatric and neurological diseases. Peptides. 2000. ↩︎
Cousino MA, et al. Neurotensin receptor alterations in Alzheimer's disease. Journal of Neurochemistry. 1995. ↩︎